[1]Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006;354(8):841-848.[2]Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev. 2006;58(2):212-225. [3]Hashimoto S, Setareh M, Ochs RL, et al. Fas/Fas ligand expression and induction of apoptosis in chondrocytes. Arthritis Rheum. 1997;40(10):1749-1755. [4]Kim SJ, Ju JW, Oh CD, et al. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis in chondrocytes in association with p53, caspase-3 and differentiation status. J Biol Chem. 2002;277(2):1332-1339. [5]Wei L, Sun XJ, Wang Z, et al. CD95-induced osteoarthritis chondrocyte apoptosis and necrosis: dependency on p38 mitogen-activated protein kinase. Arthritis Res Ther.2006; 8(2):R37. [6]Menqshol JA, Vincenti MP, Coon CI, et al. Interleukin -1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N -terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase3. Arthritis Rheum. 2000;43(4): 801-811.[7]Zhang PJ, Zhu LX, Geng XP. Anhui Yiyao. 2010;14(5): 596-598.张频捷,朱立新,耿小平. p38 MAPK信号传导通路及其抑制剂的研究现状[J]. 安徽医药,2010,14(5):596-598. [8]Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-98. [9]Morazzani M, de Carvalho DD, Kovacic H, et al. Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: Implication of ROS-p38 MAPK-integrin alpha2betal pathway. Int J Cancer. 2004;110(6):788-799. [10]张文军,李荣山. p38丝裂原活化蛋白激酶通路及其研究进展[J]. 医学综述,2007,13(9):663-665.[11]Han J, Lee JD, Bibbs L, et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994;265(5173):808-811 . [12]Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem Sci. 2007;32(8):364-371. [13]于波,朱振安. 骨关节炎治疗靶点p38MAPK信号通路研究进展[J]. 国际骨科学杂志,2011,32(6):343-345.[14]Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273(3): 1741-1748. [15]Cazillis M, Bringuier AF. Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells. Oncogene. 2004;23(27):4735-4744.[16]Obata T, Brown GE, Yaffe MB. MAP kinase pathways activated by stress: the p38MAPK pathway. Crit Care Med. 2000;28(4):67-77. [17]Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases ) in the myocardium. Circ Res. 1998;83(4):345-352. [18]Suzuki M, Tetsuka T, Yoshida S, et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha-or IL-1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett. 2000;465(1):23-27. [19]Juo P, Kuo CJ, Reynolds SE, et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol Cell Biol. 1997;17(1):24-35. [20]Badger AM, Cook MN, Lark MW, et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol. 1998;161(1):467-473. [21]Qin ST, Jiang Q, Huang JH, et al. Zhongguo Guzhi Susong Zazhi. 2008;14(11):776-781.秦泗通,蒋青,黄际河,等. p38 丝裂原活化蛋白激酶抑制剂对大鼠骨性关节炎的影响[J]. 中国骨质疏松杂志,2008,14(11): 776-781.[22]Robbins JR, Thomas B, Tan L, et al. Immortalized human adult articular chondrocytes maintain cartilage-specific phenotype and responses to interleukin-1beta. Arthritis Rheum. 2000;43:2189-2201. [23]Murata M, Yudoh K, Nakamura H, et al. Distinct signaling pathways are involved in hypoxia-and IL-1-induced VEGF expression in human articular chondrocytes. J Orthop Res.2006;24(7):1544-1554. [24]Mengshol JA, Vincenti MP, Coon CI, et al. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB :differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000; 43(4):801-811. [25]Liacini A, Sylvester J, Li WQ, et al. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1(AP-1) and nuclear factor kappa B ( NF- kappa B ) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biology. 2002;21(3):251-262. [26]Radons J, Bosserhoff AK, Grassel S, et al. p38MAPK mediates IL-1- induced down-regulation of aggrecan gene expression in human chondrocytes. Int J Mol Med. 2006; 17(4):661-668. [27]Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibits th interleukin-1β -induced activation of MKK-3, p38α-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. Arthritis Res Ther. 2010;12(5):R195. [28]Chowdhury TT, Salter DM, Bader DL, Lee DA. Signal transduction pathways involving p38 MAPK, JNK, NF kappaB and AP-1 influences the response of chondrocytes cultured in agarose constructs to IL-1beta and dynamic compression. Inflamm Res. 2008;57(7):306-313. [29]Ding L, Guo D, Homandberg GA. The cartilage chondrolytic mechanism of fibronectin fragments involves MAP kinases: comparison of three fragments and native fibronectin. Osteoarthritis Cartilage. 2008 Oct;16(10):1253–1262. [30]Zayed N, Li X, Chabane N, et al. Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. Arthritis Res Ther. 2008;10(6):R146. [31]Prasadam I, van Gennip S, Friis T, et al. ERK-1/2 and p38 in the regulation of hypertrophic changes of normal articular cartilage chondrocytes induced by osteoarthritic subchondral osteoblasts. Arthritis Rheum. 2010;62(5):1349-1360.[32]Morel C, Ibarz G, Oiry C, et al. Cross-interactions of two p38 mitogen-activated protein (MAP) kinase inhibitors and two cholecystokinin (CCK) receptor antagonists with the CCK1 receptor and p38 MAP kinase. J Biol Chem. 2005;280(22): 21384-21393. [33]Lim H, Kim HP. Matrix metalloproteinase-13 expression in IL-1β-treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways. Arch Pharm Res. 2011;34(1):109-117. [34]Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy.Immunopharmacology.2000;47(2-3):185-201. [35]Long DL, Loeser RF. 38gamma mitogen-activated protein kinase suppresses chondrocyte production of MMP-13 in response to catabolic stimulation. Osteoarthritis Cartilage. 2010;18(9):1203-1210. [36]Hamamura K, Goldring MB, Yokota H. Involvement of p38 MAPK in regulation of MMP-13 mRNA in chondrocytes in response to surviving stress to endoplasmic reticulum. Arch Oral Biol. 2009;54:279-286. [37]Joos H, Albrecht W, Laufer S, et al. Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta- stimulated human chondrocytes. Br J Pharmacol. 2010; 160(5):1252-1262. [38]Stanton LA, Sabari S, Sampaio AV, et al. p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation. BioChem J. 2004;378(1):53-62. [39]Nick JA, Young SK, Arndt PG, et al. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. Jimmunol. 2002;169(9):5260-5269. [40]Brown KK, Heitmeyer SA, Hookfin EB, et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008;5:22. [41]Namdari S, Wei L, Moore D, et al. Reduced limb length and worsened osteoarthritis in adult mice after genetic inhibition of p38 MAP kinase activity in cartilage. Arthritis Rheum. 2008; 58(11): 3520-3529. [42]Li TF, Gao L, Sheu TJ, et al. Aberrant hypertrophy in smad3-deficient murine chondrocytes is rescued by restoring transforming growth factor beta-activated kinase 1/activating transcription factor 2 signaling:a potential clinical implication for osteoarthritis. Arthritis Rheum.2010;62(8):2359-2369.[43]Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibitors the interleukin-1β-induced activation of MKK-3,p38α-MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. Arthritis Research & Therapy.2010;12(5):R195.[44]牛振东,刘恒,曹瑞治,等. 骨关节炎病理进程相关机制的研究进展[J]. 华西医学, 2012,27(11):1741-1744.[45]范素芳,王文雅,张柳. 丝裂原活化蛋白激酶信号通路对骨关节炎软骨的作用[J]. 中国组织工程研究,2012,16(37):7015-7019.[46]杨丰建,俞永林,林伟龙,等. 骨关节炎家兔关节软骨中丝裂原活化蛋白激酶信号通路蛋白表达以及活化状况[J]. 复旦学报:医学版,2011,38(3):221-225. |